Vaginal Fetal Fibronectin Levels and Spontaneous Preterm Birth in Symptomatic Women

  title={Vaginal Fetal Fibronectin Levels and Spontaneous Preterm Birth in Symptomatic Women},
  author={George C. Lu and Robert L Goldenberg and Suzanne P. Cliver and Usha Seshadri Kreaden and William W. Andrews},
  journal={Obstetrics \& Gynecology},

Tables from this paper

Interleukins & Fetal Fibronectin Levels In Preterm Delivery

C cervicovaginal measurement of fetal fibronectin, IL-lB and IL-8 in combination with clinical findings may be useful for the evaluation of patients with threatened premature delivery.

Fetal Fibronectin and Adverse Infant Outcomes in a Predominantly Human Immunodeficiency Virus–Infected African Population: A Randomized Controlled Trial

In a population of predominantly HIV- infected African women, fetal fibronectin concentrations at 28 but not at 20–24 weeks were associated with increased risk of preterm birth, and the associations were stronger for early pre term birth and when fetal fibronsectin levels were higher.

Interleukin 6 and fetal fibronectin as a predictors of preterm delivery in symptomatic patients.

The combination of both tests performed better than the individual tests and decreased the false positive rate, which in turn reduced the chances for inappropriate patient treatment, bringing down the costs.

The value of fetal fibronectin in cervicovaginal secretions and standard markers of infection in predicting preterm delivery for patients with symptoms and intact membranes

The detection of fetal fibronectin in cervicovaginal secretions allows identification of patients at high risk of preterm delivery, and high level of C-reactive protein and white blood cells count appear to correlate with increased rate of prematurity.

Evaluation of a quantitative fetal fibronectin test for spontaneous preterm birth in symptomatic women.

Comparison of maternal and neonatal outcome before and after the availability of a rapid assay for fetal fibronectin at a tertiary level maternity hospital

Findings suggest that implementation of FFN testing in clinical settings takes time and requires more rigorous policies for use to replicate previous research findings, and that predictive algorithms using the best evidence and predictive factors for subpopulations may lead to improved diagnostic precision in the future.

Examining the relationship between positive mid-gestational fetal fibronectin assays and histological evidence of acute placental inflammation

No association exists between positive fetal fibronectin assays and acute histologic placental inflammation at birth and women with positive assays were no more likely to have histological evidence of acute inflammation noted at birth.



Fetal fibronectin in patients at increased risk for premature birth.

Fetal fibronectin improves the accuracy of diagnosis of preterm labor.

Fetal fibronectin as a predictor of preterm birth in patients with symptoms: a multicenter trial.

Fetal fibronectin in cervical and vaginal secretions as a predictor of preterm delivery.

The presence of cervicovaginal fetal fibronectin in the second and third trimesters of pregnancy identifies a subgroup of women who are at high risk for preterm delivery.

The preterm prediction study: quantitative fetal fibronectin values and the prediction of spontaneous preterm birth. The National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network.

Increasing levels of cervicovaginal fetal fibronectin up to 300 ng/mL are associated with an increasing risk of spontaneous preterm birth, and at 24 to 30 weeks, the value currently used appears to be a reasonable cutoff point for predicting spontaneous pre term birth at <35 weeks' gestation.


Fetal fibronectin in cervicovaginal secretions is associated with preterm delivery in both high-risk and low-risk women.